Filtered By:
Specialty: Cardiology
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 545 results found since Jan 2013.

Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores
CONCLUSIONS: In PCI patients with a high ischemic and bleeding risk, the ticagrelor antiplatelet strategy significantly reduced the MACCE rate without increasing the risk of major bleeding. A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group.PMID:34154742 | PMC:PMC8322751 | DOI:10.1016/j.ihj.2021.02.002
Source: Indian Heart J - June 22, 2021 Category: Cardiology Authors: Peng Xiao Feng Xie Yunjing Lan Source Type: research

Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials
ConclusionsIn patients receiving TAVR, a therapeutic strategy of aspirin or OAC with clopidogrel significantly increases the risk of major bleeding without impact on mortality and ischemic outcomes compared to aspirin or OAC without clopidogrel. The performance of different antithrombotic regimens in terms of long-term clinical outcomes and bioprosthesis valve function requires further investigation.Graphic abstractForest plots from pairwise and network meta-analyses associated with an antithrombotic therapy with or without clopidogrel Risk ratio for all outcomes of interest calculated with the pairwise meta-analysis (left...
Source: Clinical Research in Cardiology - January 1, 2022 Category: Cardiology Source Type: research

Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials
Abstract: Considering that there is no definite conclusion on the efficacy and safety of switching from potent P2Y12 inhibitors to clopidogrel, we conducted a systematic review and meta-analysis of patients with acute coronary syndromes undergoing percutaneous coronary intervention and compared the efficacy and safety of de-escalation or not of antiplatelet therapy. The relevant randomized controlled trials were included by searching several databases. Net adverse clinical events were identified as the composite end point, which was defined as a composite of cardiovascular death, myocardial infarction, revascularizatio...
Source: Journal of Cardiovascular Pharmacology - August 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research

Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research

Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research

Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial ...
Source: Atherosclerosis - January 10, 2023 Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research

Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials
Conclusion: Ticagrelor increased the risk of bleeding and did not increase treatment efficacy compared to that of clopidogrel in the East Asian population who have ACS treated with PCI.
Source: Cardiology - April 24, 2023 Category: Cardiology Source Type: research

Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis
ConclusionsWhen compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
Source: American Journal of Cardiovascular Drugs - August 2, 2023 Category: Cardiology Source Type: research